MaxCyteMXCT
Fair Value
US$9
Share price27 Dec
US$1.2885.8% undervalued intrinsic discount
1Y-43.11%
7D4.06%
Cell And Gene Therapy Tailwinds Will Drive Meaningful Long Term Upside Potential
AN
Analyst High Target compiles bullish analysts opinions to create narratives which represent one standard deviation above the consensus price target, using forecasted revenue and earnings figures, as well as the transcripts of earnings calls
Published
27 Dec 25
Views
4
Not Invested